NASDAQ · FTH
Faeth Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FTH: Nov 13, 2026
Faeth Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.66. The reported EPS for the same quarter last year was $-3.62.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.66 | $-0.58 | $-0.73 | 4 |
| Dec 2026 | $-0.68 | $-0.60 | $-0.80 | 5 |
| Mar 2027 | $-0.64 | $-0.61 | $-0.69 | 3 |
| Jun 2027 | $-0.66 | $-0.63 | $-0.71 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · RTTNews · Zacks- Fintel · Oct 27, 10:42 AM EDTSensei Biotherapeutics, Inc. Appoints Adam Schayowitz to Board of Directors on October 23, 2026On October 23, 2026, the Board of Directors of Faeth Therapeutics, Inc., also known as Sensei Biotherapeutics, Inc., increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately. Dr. Schayowitz w
- MarketBeat · Oct 7, 4:02 AM EDTSensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial ReadoutFaeth Therapeutics outlined its clinical strategy for PIKTOR, an oral combination designed to inhibit the PI3K/AKT/mTOR, or PAM, pathway at multiple points, during an analyst and investor event. The company is developing the regimen in endometrial cancer and hormone receptor-posi
- Fintel · Sep 14, 10:28 PM EDTLucid Capital Markets Initiates Coverage of Faeth Therapeutics with BuyFintel reports that on September 14, 2026, LUCID CAPITAL MARKETS initiated coverage of Faeth Therapeutics (NASDAQCM:FTH) with a Buy recommendation. The closing price of the stock on the day of the rating action, September 14, 2026, was $39.02. This follows a closing price of $37.
- RTTNews · Sep 9, 3:06 AM EDTBiotech Stocks At 52-Week Highs – PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH(RTTNews) – The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 recep
- RTTNews · Sep 3, 4:08 AM EDTBiotech Stocks At 52-Week Highs – OABI +13%, FRNM, EXEL, FTH, LFST(RTTNews) – The following biotech stocks reached a 52-week high on September 2, 2026, driven by achieving new regulatory milestones or positive financial results.
- Zacks · Sep 1, 12:00 PM EDTWhat Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Aug 24, 9:55 AM EDTWall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should KnowThe mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- RTTNews · Aug 10, 2:24 PM EDTFaeth Therapeutics Gains 18% As PIKTOR Approaches Phase 2 Endometrial Cancer Data(RTTNews) – Shares of Faeth Therapeutics, Inc. (FTH) are up over 18% today.
- RTTNews · Jul 13, 7:17 AM EDTBiotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH(RTTNews) – The following biotech stocks touched a 52-wek high on July 10, 2026, driven by key catalysts like encouraging regulatory updates and quarterly results.
- RTTNews · Jun 22, 11:10 PM EDTTop Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA(RTTNews) – Monday's top gainers include Tenon, following a Form S-1 filing; Azitra, which recently outlined its strategic reorientation and 2026 outlook; Nuvectis, after announcing a licensing deal with Haisco; and REGENXBIO, which is gearing up to resubmit its BLA for its Hunte
- RTTNews · Jun 17, 11:15 PM EDTTop Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch(RTTNews) – Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in pancreatic cancer trial; Lunai, after its CEO
- RTTNews · Jun 14, 10:02 PM EDTTop Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch(RTTNews) – Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; and Alumis, which is advancing its lead th
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Faeth Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.